Applications of Genetics, Genomics and Bioinformatics in Drug Discovery

Richard Bourgon¹, Frederick E. Dewey², Zhengyan Kan³, Shuyu D. Li^4,5

¹Genentech Inc.
²Regeneron Genetics Center
³Pfizer Inc
⁴Sema4, a Mount Sinai venture
⁵Icahn School of Medicine at Mount Sinai
Email: bourgon.richard@gene.com, frederick.dewey@regeneron.com, Zhengyan.Kan@pfizer.com, shuyu.li@sema4genomics.com

Pacific Symposium on Biocomputing 23:1-7(2018)

© 2018 World Scientific
Open Access chapter published by World Scientific Publishing Company and distributed under the terms of the Creative Commons Attribution (CC BY) 4.0 License.

Abstract

As the impact of genetics, genomics, and bioinformatics on drug discovery has been increasingly recognized, this session of the 2018 Pacific Symposium on Biocomputing (PSB) aims to facilitate scientific discussions between academia and pharmaceutical industry on how to best apply genetics, genomics and bioinformatics to enable drug discovery. The selected papers focus on developing and applying computational approaches to understand drug mechanisms of action and develop drug combination strategies, to enable in silico drug screening, and to further delineate disease pathways for target identification and validation.